State of the Art in Tumor Antigen and Biomarker Discovery

Our knowledge of tumor immunology has resulted in multiple approaches for the treatment of cancer. However, a gap between research of new tumors markers and development of immunotherapy has been established and very few markers exist that can be used for treatment. The challenge is now to discover n...

Descripción completa

Detalles Bibliográficos
Autores principales: Even-Desrumeaux, Klervi, Baty, Daniel, Chames, Patrick
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Molecular Diversity Preservation International (MDPI) 2011
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3757432/
https://www.ncbi.nlm.nih.gov/pubmed/24212823
http://dx.doi.org/10.3390/cancers3022554
_version_ 1782282213631459328
author Even-Desrumeaux, Klervi
Baty, Daniel
Chames, Patrick
author_facet Even-Desrumeaux, Klervi
Baty, Daniel
Chames, Patrick
author_sort Even-Desrumeaux, Klervi
collection PubMed
description Our knowledge of tumor immunology has resulted in multiple approaches for the treatment of cancer. However, a gap between research of new tumors markers and development of immunotherapy has been established and very few markers exist that can be used for treatment. The challenge is now to discover new targets for active and passive immunotherapy. This review aims at describing recent advances in biomarkers and tumor antigen discovery in terms of antigen nature and localization, and is highlighting the most recent approaches used for their discovery including “omics” technology.
format Online
Article
Text
id pubmed-3757432
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Molecular Diversity Preservation International (MDPI)
record_format MEDLINE/PubMed
spelling pubmed-37574322013-09-04 State of the Art in Tumor Antigen and Biomarker Discovery Even-Desrumeaux, Klervi Baty, Daniel Chames, Patrick Cancers (Basel) Review Our knowledge of tumor immunology has resulted in multiple approaches for the treatment of cancer. However, a gap between research of new tumors markers and development of immunotherapy has been established and very few markers exist that can be used for treatment. The challenge is now to discover new targets for active and passive immunotherapy. This review aims at describing recent advances in biomarkers and tumor antigen discovery in terms of antigen nature and localization, and is highlighting the most recent approaches used for their discovery including “omics” technology. Molecular Diversity Preservation International (MDPI) 2011-06-09 /pmc/articles/PMC3757432/ /pubmed/24212823 http://dx.doi.org/10.3390/cancers3022554 Text en © 2011 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).
spellingShingle Review
Even-Desrumeaux, Klervi
Baty, Daniel
Chames, Patrick
State of the Art in Tumor Antigen and Biomarker Discovery
title State of the Art in Tumor Antigen and Biomarker Discovery
title_full State of the Art in Tumor Antigen and Biomarker Discovery
title_fullStr State of the Art in Tumor Antigen and Biomarker Discovery
title_full_unstemmed State of the Art in Tumor Antigen and Biomarker Discovery
title_short State of the Art in Tumor Antigen and Biomarker Discovery
title_sort state of the art in tumor antigen and biomarker discovery
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3757432/
https://www.ncbi.nlm.nih.gov/pubmed/24212823
http://dx.doi.org/10.3390/cancers3022554
work_keys_str_mv AT evendesrumeauxklervi stateoftheartintumorantigenandbiomarkerdiscovery
AT batydaniel stateoftheartintumorantigenandbiomarkerdiscovery
AT chamespatrick stateoftheartintumorantigenandbiomarkerdiscovery

Ejemplares similares